Testing an Experimental Anti-Cancer Drug Called Venetoclax for High Grade B-cell Lymphomas

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Logo Image
"Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!"
Age: 18 years or older
Gender:
Any
Healthy Volunteers: No
Keywords: B-cell Lymphoma, High Grade B-cell Lymphomas, Double-Expressing Lymphomas
Type: Drug study, Phase [/2/,/ /3/]
Target:
33 Participants
Investigator:
Description
This study is being done to answer the following question:

Can we lower the chance of your lymphoma returning or getting worse by adding a new drug to the usual combination of drugs?

We are doing this study because we want to find out if this approach is better or worse than the usual approach for your lymphoma. The usual approach is defined as care most people get for double-hit or double expressing lymphoma.
This study requires

The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.

Who can participate

The study team will discuss study eligibility criteria with you.

Benefits and risks of participating
BENEFITS:

We cannot promise any benefits to you as a result of taking part in this research study.


RISKS:

The study team will discuss the risks associated with taking part in this research study.
Compensation
You will not be paid to take part in this research study.
Resources
Schedule
Study duration and period
After you finish study treatment, your doctor will continue to follow your condition and watch you for side effects for up to 5 years. You will have clinic visits every 3 months for 2 years. Then every 6 months until 5 years after you are registered to the study. After 5 years, your doctor will follow up with you either in clinic or by phone every 6 months for up to 10 years after you registered to the study.
Recruitment period
From Nov. 6, 2019
Location
UC Davis Comprehensive Cancer Center
4501 X Street
Sacramento, CA 95817
Contact
Micaela Rodriguez
Research Topic
Conditions:
  • Diffuse Large B-Cell Lymphoma
  • Double-Expressor Lymphoma
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma
  • Not Otherwise Specified
  • Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview